iLoF listed as one of the top 150 digital health start-ups worldwide by CB Insight’s
14 August 2020
Just as we prepare to announce the two challenge areas selected for this year’s Wild Card programme, iLoF has been included in a prestigious list recognised throughout the health industry.
iLoF received Wild Card support so that they could develop a solution using artificial intelligence (AI) and photonics to screen for Alzheimer’s disease, as current screening techniques are invasive and painful. Using its non-invasive, portable and inexpensive test, iLoF seeks to transform the patients’ experience and make clinical trials convenient and patient-centric. iLoF says it hopes to save 40% of the total costs and 70% of the time spent on screening and stratifying Alzheimer’s patients for clinical trials, thereby becoming an enabler in finding treatments for the disease.
Since their launch through the Wild Card programme, iLoF has been gaining investment and recognition with their latest honours being inclusion in CB Insights’ Digital Health 150. The 150 companies on this list were selected based on factors including patent activity, business relations, investor profile, news sentiment analysis, proprietary Mosaic scores, market potential, competitive landscape, team strength and tech novelty.
Become a game-changerNewsletter
Subscribe to our newsletter and be the first to learn about the next call opening